Available data and models for the health-economic evaluation of treatment in Alzheimer's disease (AD) have limitations causing uncertainty to decision makers. Forthcoming treatment strategies in preclinical or early AD warrant an update on the challenges associated with their economic evaluation.
from Dementia Big http://ift.tt/2iKeghV via alcoholic dementia
http://ift.tt/2hTxHFv
No comments:
Post a Comment